DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study to Assess Change in Disease Activity and Adverse Events of RINVOQ in Adult Participants With Ankylosing Spondylitis in the Real-World Japan

Recruiting

Conditions: Ankylosing Spondylitis

First Posted Date: 2022-11-08

Last Posted Date: 2024-08-19

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT05609643

Locations: 🇯🇵
Yagi Hospital /ID# 251078, Fukuoka-shi, Fukuoka, Japan
🇯🇵
Kunou Orthopedic Clinic /ID# 252168, Kitakyushu-shi, Fukuoka, Japan
🇯🇵
Kobe Kaisei Hospital /ID# 251073, Kobe-shi, Hyogo, Japan

and more 55 locations

A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique

Phase 2

Withdrawn

Conditions: Ventral Hernia
Abdominal Hernia

Interventions: Drug: BOTOX Dose A
Drug: BOTOX Dose C
Drug: BOTOX Dose B
Drug: Placebo for BOTOX

First Posted Date: 2022-11-07

Last Posted Date: 2024-05-16

Lead Sponsor: AbbVie

Registration Number: NCT05606757

Locations: 🇺🇸
Atrium Health Carolinas Medical Center /ID# 247711, Charlotte, North Carolina, United States
🇺🇸
NYU Langone Hospital - Long Island /ID# 251280, Mineola, New York, United States

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Dupilumab
Drug: Upadacitinib

First Posted Date: 2022-11-01

Last Posted Date: 2025-02-14

Lead Sponsor: AbbVie

Target Recruit Count: 920

Registration Number: NCT05601882

Locations: 🇺🇸
Medical Dermatology Specialists /ID# 250212, Phoenix, Arizona, United States
🇺🇸
Alliance Dermatology and Mohs Center /ID# 249671, Phoenix, Arizona, United States
🇺🇸
Clinical Trials Institute - Northwest Arkansas /ID# 249838, Fayetteville, Arkansas, United States

and more 254 locations

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: ABBV-706
Drug: Budigalimab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2022-10-31

Last Posted Date: 2025-04-27

Lead Sponsor: AbbVie

Target Recruit Count: 350

Registration Number: NCT05599984

Locations: 🇪🇸
Hospital Santa Creu i Sant Pau /ID# 257294, Barcelona, Spain
🇪🇸
Hospital Universitario Ramon y Cajal /ID# 257291, Madrid, Spain
🇪🇸
Hospital Universitario Fundacion Jimenez Diaz /ID# 257295, Madrid, Spain

and more 62 locations

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia

Recruiting

Conditions: Acute Myeloid Leukemia

First Posted Date: 2022-10-19

Last Posted Date: 2024-08-12

Lead Sponsor: AbbVie

Target Recruit Count: 70

Registration Number: NCT05587049

Locations: 🇨🇴
Sociedad de Oncologia y Hematologia del Cesar /ID# 248615, Valledupar, Cesar, Colombia
🇨🇴
Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 248570, Bogota DC, Cundinamarca, Colombia
🇨🇴
Fundacion Valle Del Lili /ID# 248294, Cali, Valle Del Cauca, Colombia

and more 4 locations

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: ABBV-668

First Posted Date: 2022-10-06

Last Posted Date: 2025-01-08

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT05570006

Locations: 🇺🇸
Gastro SB /ID# 249271, Chula Vista, California, United States
🇺🇸
Ctr for Advanced Gastroenterol /ID# 249226, Maitland, Florida, United States
🇺🇸
Atlantic Medical Research /ID# 249213, Margate, Florida, United States

and more 27 locations

Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Risankizumab Dose A
Drug: Risankizumab Dose B

First Posted Date: 2022-10-05

Last Posted Date: 2023-04-28

Lead Sponsor: AbbVie

Target Recruit Count: 198

Registration Number: NCT05567029

Locations: 🇺🇸
Anaheim Clinical Trials LLC /ID# 250098, Anaheim, California, United States
🇺🇸
Bio-Kinetic Clinical Applications, LLC /ID# 250181, Springfield, Missouri, United States
🇺🇸
PPD Clinical Research Unit - Austin /ID# 250672, Austin, Texas, United States

and more 2 locations

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

Phase 1

Completed

Conditions: ABBV-154

Interventions: Drug: ABBV-154 Dose Formulation A
Drug: ABBV-154 Dose Formulation B

First Posted Date: 2022-09-27

Last Posted Date: 2023-03-13

Lead Sponsor: AbbVie

Target Recruit Count: 40

Registration Number: NCT05556226

Locations: 🇺🇸
Acpru /Id# 250429, Grayslake, Illinois, United States
🇺🇸
PPD Clinical Research Unit -Las Vegas /ID# 250650, Las Vegas, Nevada, United States

Effect of Long-term Psoriasis on Patients' Life - CORONATE

Completed

Conditions: Psoriasis

First Posted Date: 2022-09-27

Last Posted Date: 2024-10-26

Lead Sponsor: AbbVie

Target Recruit Count: 543

Registration Number: NCT05555953

Locations: 🇮🇹
AZIENDA USL TOSCANA CENTRO - Piero Palagi /ID# 245569, Florence, Firenze, Italy
🇮🇹
Ospedale San Martino /ID# 245641, Genoa, Genova, Italy
🇮🇹
Policlinico Agostino Gemelli /ID# 245570, Rome, Roma, Italy

and more 12 locations

A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom

Completed

Conditions: Chronic Lymphocytic Leukemia

First Posted Date: 2022-09-27

Last Posted Date: 2024-05-17

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT05555979

Locations: 🇬🇧
Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 252720, Norwich, Norfolk, United Kingdom
🇬🇧
Oxford University Hospitals NHS Foundation Trust /ID# 252715, Oxford, Oxfordshire, United Kingdom
🇬🇧
Barts Health NHS Trust /ID# 252717, London, London, City Of, United Kingdom

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy